Results 61 to 70 of about 1,322,013 (311)

Endothelial p300 promotes portal hypertension and hepatic fibrosis through CCL2-mediated angiocrine signaling

Hepatology, 2020
During liver fibrosis, liver sinusoidal endothelial cells (LSECs) release angiocrine signals to recruit inflammatory cells into the liver. p300, a master regulator of gene transcription, is associated with pathological inflammatory response.
Jinhang Gao, Bo Wei, Mengfei Liu, P. Hirsova, Tejasav S. Sehrawat, Sheng Cao, Xiao Hu, Fei Xue, Usman Yaqoob, N. Kang, Huarui Cui, W. Pomerantz, Enis Kostallari, V. Shah   +13 more
semanticscholar   +1 more source

Association of blood cadmium levels with all-cause and cause-specific mortality among adults with non-alcoholic fatty liver disease: a prospective cohort study

Frontiers in Public Health
BackgroundCadmium (Cd) accumulates in the body over time, damaging organs such as the liver, kidneys, and brain. Some researchers have suggested that elevated blood Cd levels may contribute to the onset and progression of nonalcoholic fatty liver disease
Congxi Xu, Congxi Xu, Zhi Li, Shirui Hao, Jian Zhang, Jinlong Li, Kuopeng Liang, Xiaojuan Wang, Yi Zhang, Yi Zhang, Guangyuan Zhao, Mengyun Bai, Dengxiang Liu, Jitao Wang   +13 more
doaj   +1 more source

The peculiarities of macroscopic status of the upper gastrointestinal tract mucosa in patients with hepatic and extrahepatic portal hypertension.

Medičnì Perspektivi, 2018
Identification of endoscopic signs of concomitant pathology of the upper gastrointestinal tract allows to determine the tactics of managing patients with different forms of portal hypertension (PG).
Yu. M. Stepanov, N. V. Chaliy, O. V. Simonova   +2 more
doaj   +1 more source

Causes and Management of Non-cirrhotic Portal Hypertension

Current Gastroenterology Reports, 2020
Non-cirrhotic portal hypertension (NCPH) includes a heterogeneous group of conditions. The aim of this paper is to make an overview on the denominations, diagnostical features and management of porto-sinusoidal vascular disease (PSVD) and chronic portal ...
S. Gioia, S. Nardelli, L. Ridola, O. Riggio   +3 more
semanticscholar   +1 more source

Effect of skeletal muscle index on post-embolization syndrome of hepatocellular carcinoma after transarterial chemoembolization

BMC Gastroenterology
Background Skeletal muscle index (SMI) is a commonly used research method for evaluating muscle mass.However, its impact on post-embolization syndrome(PES) of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE ...
Xiaojuan Wang, Jitao Wang, Jinlong Li, Kuopeng Liang, Shoufang Dai, Ruikun Wang, Yi Zhang, Quan Ren, Linglei Meng, Yuzi Qiu   +9 more
doaj   +1 more source

Difficulties of differential diagnosis of portal hypertension: case report

Медицинский совет, 2021
In the article we analysed the difficulties of differential diagnosis of portal hypertension, considers a clinical case that illustrates the presented theoretical material.
T. V. Penkina, O. E. Berezutskaya, D. T. Dicheva, E. V. Partsvania-Vinogradova, V. S. Larina, R. M. Umyarova, D. V. Borzova, E. V. Ulyankina   +7 more
doaj   +1 more source

Risk Factors for Small‐for‐Size Syndrome Grade B/C After Simultaneous Splenectomy in Adult Living‐Donor Liver Transplantation

Annals of Gastroenterological Surgery, EarlyView.
In a single‐center cohort of 577 adult LDLT recipients who underwent simultaneous splenectomy, clinically significant SFSS grade B/C (ILTS‐iLDLT‐LTSI 2023) occurred in 18.2% and was associated with inferior graft survival. Multivariate analysis identified MELD ≥ 30, NLR ≥ 4.5, and donor age ≥ 50 years as independent risk factors, which risk rising ...
Kyohei Yugawa, Takeo Toshima, Shinji Itoh, Takashi Motomura, Shohei Yoshiya, Norifumi Iseda, Tomoharu Yoshizumi   +6 more
wiley   +1 more source

National Consensus on Portal Hypertension Management in Indonesia

Acta Medica Indonesiana, 2022
Portal hypertension is a clinical syndrome that consists of hypersplenism, ascites, gastroesophageal varices, and encephalopathy. This condition is marked by increased portal pressure gradient and may occur with or without liver cirrhosis.
Juferdy Kurniawan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Putut Bayupurnama, Muhammad Begawan Bestari, Fardah Akil, Rino Alvani Gani, Irsan Hasan   +7 more
doaj   +2 more sources

Non-cirrhotic portal fibrosis

International Journal of Advanced Medical and Health Research, 2014
Portal hypertension occurs commonly in patients with cirrhosis and rarely in those without cirrhosis of liver. The two most important causes of non-cirrhotic portal hypertension are non-cirrhotic portal fibrosis (NCPF) and extrahepatic portal venous ...
Venkatesan Mukta, Kalaimani Sivamani, Lakshmi C Panicker   +2 more
doaj   +1 more source

Immunogenicity and safety of a booster COVID‐19 vaccination in patients with chronic liver disease: A multicenter study

Portal Hypertension & Cirrhosis, 2023
Aim Patients with chronic liver disease (CLD), especially cirrhosis, are at a high risk of severe illness or death from coronavirus disease‐2019 (COVID‐19) and may have a suboptimal immune response to the severe acute respiratory syndrome coronavirus 2 ...
Jitao Wang, Jingwen Ai, Huiling Xiang, Yanliang Zhang, Zhiyun Hou, Qiran Zhang, Jiaojian Lv, Shubo Chen, Chuan Liu, Qianqian Li, Jing Liang, Faren Xie, Shujun Jiang, Nina Zhang, Aiguo Zhang, Xiaolin Lan, Xuying Zhang, Jinlong Li, Dengxiang Liu, Wenchuan Wang, Wei Rao, Zhang Qun, Qiuju Tian, Xiaolong Qi, Wenhong Zhang   +24 more
doaj   +1 more source